Advertisement

Cancer and Metastasis Reviews

, Volume 24, Issue 4, pp 569–584 | Cite as

Development and regulation of monoclonal antibody products: Challenges and opportunities

  • Wendy C. Weinberg
  • Michelle R. Frazier-Jessen
  • Wen Jin Wu
  • Andrea Weir
  • Melanie Hartsough
  • Patricia Keegan
  • Chana Fuchs
Article

Summary

An increasing number of monoclonal antibodies for cancer diagnosis and treatment are in clinical use and in the development pipeline, with more expected as new molecular targets are identified. As with all drugs, product quality, an appropriate pre-clinical pharmacology-toxicology testing program, and well-designed clinical trials are essential for a successful drug development program. However, protein products such as monoclonal antibodies present unique regulatory concerns. The derivation from biological sources as well as the constantly evolving technologies utilized to develop these products demands continuous appraisal of safety concerns, even while the accumulated experience with these protein products has facilitated their safety evaluations. Because of the complex nature of these products and their inherent heterogeneity, a mechanistic understanding of the mode of action along with careful attention to product design and manufacture are critical to assuring a safe, effective and consistent product. Protein products may be highly species specific, thus pharmacologically relevant animal models are an important component in accurately assessing pre-clinical safety and establishing initial dosing. Furthermore, the immunogenicity of protein products can impact its safety profile, dose exposure, and efficacy. Mechanistic insight should form the basis of biological assays used for monitoring efficacy, safety, lot-to-lot consistency and manufacturing changes. The inherent uniqueness of each product necessitates a flexible case-by-case approach for biologics review that is based on a strong scientific understanding of relative risks. This review will provide an overview of approaches used in the development of antibody-based cancer therapeutics and the scientific basis of regulatory reviews.

Keywords

monoclonal antibodies Investigational New Drug (IND) cancer therapy Biologics License Application (BLA) clinical trials immunogenicity 

Abbreviation

NHL

Non-Hodgkins Lymphoma

mAb

monoclonal antibody

IND

Investigational New Drug application

FDA

Food and Drug Administration

ADCC

antibody dependent cell mediated cytotoxicity

CDC

complement dependent cytotoxicity

Ig

immunoglobulin

HAMA

human anti-mouse antibody

CFR

Code of Federal Regulations

PTC

Points to Consider

ICH

International Conference on Harmonisation

PrPsc

infectious prion protein

BLA

Biologics License Application

PAS

Prior Approval Supplement

CEA

carcinoembryonic antigen

FDAMA

FDA Modernization Act

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lucisano Valim, YM Lachmann, PJ: The effect of antibody isotype and antigenic epitopedensity on the complement-fixing activity of immune complexes: A systematic study usingchimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol 84: 1–8, 1991Google Scholar
  2. 2.
    Mimura Y, Ghirlando R, Sondermann P, Lund J, Jefferis R: The molecular specificity of Ig G-Fc interactions with Fc gamma receptors. Adv Exp Med Biol 495: 49–53, 2001PubMedGoogle Scholar
  3. 3.
    Center for Biologics Evaluation and Research: Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use.1997Google Scholar
  4. 4.
    van der Zee JS, van Swieten P, Aalberse RC: Serologic aspects of Ig G4 antibodies.II. Ig G4 antibodies form small, nonprecipitating immune complexes due to functionalmonovalency. J Immunol 137: 3566–3571, 1986PubMedGoogle Scholar
  5. 5.
    Aalberse RC, Schuurman J: Ig G4 breaking the rules. Immunology 105(1): 9–19, 2002CrossRefPubMedGoogle Scholar
  6. 6.
    ICH Topic Q5E: Comparability of Biotechnological/Biological Products Subject to Changesin their Manufacturing Process 2004Google Scholar
  7. 7.
    US Food and Drug Administration: Comparability Protocols℄Protein Drug Products and Biological Products℄Chemistry, Manufacturing, and Controls Information: draftguidance 2003Google Scholar
  8. 8.
    US Food and Drug Administration: FDA Guidance Concerning Demonstration of Comparabilityof Human Biological Products, Including Therapeutic Biotechnology-derived Products 1996Google Scholar
  9. 9.
    ICH Topic Q1A(R2): Stability Testing of New Drug Substances and Products (Second Revision). Federal Register, 68(225): 65717–65718, November 21, 2003Google Scholar
  10. 10.
    ICH Topic Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Federal Register, 64: 44928, August 18, 1999Google Scholar
  11. 11.
    Sadick MD, Intintoli A, Quarmby V, McCoy A, Canova-Davis E, Ling V: Kinasereceptor activation (KIRA): a rapid and accurate alternative to end-point bioassays. JPharm Biomed Anal 19: 883–891, 1999Google Scholar
  12. 12.
    Serabian MA, Pilaro AM: Safety assessment of biotechnology-derived pharmaceuticals:ICH and beyond. Toxicol Pathol 27: 27–31, 1999PubMedCrossRefGoogle Scholar
  13. 13.
    ICH Topic S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals.Federal Register, 62(222): 61515, November 18, 1997:1997Google Scholar
  14. 14.
    1 US Food and Drug Administration: Product Approval Information–Licensing Action, Rituximab Formulated Bulk. Center for Drug Evaluation and Research, 1997Google Scholar
  15. 15.
    Treacy, G: Using an analogous monoclonal antibody to evaluate the reproductive andchronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody. Hum Exp Toxicol 19: 226–228, 2000CrossRefPubMedGoogle Scholar
  16. 16.
    Clarke J, Leach W, Pippig S, Joshi A, Wu B, House R, Beyer J: Evaluation of asurrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody.Regul Toxicol Pharmacol 40: 219–226, 2004CrossRefPubMedGoogle Scholar
  17. 17.
    ICH Topic S7A: Safety Pharmacology Studies for Human Pharmaceuticals. Federal Register 66(135): 36791–36792; July 13, 2001Google Scholar
  18. 18.
    Wilson NH, Hardisty JF, Hayes JR: Short-term, subchronic, and chronic toxicologystudies. In: Hayes AW (ed) Principles and Methods of Toxicology. Taylor and Francis, Philadelphia, 2001, pp 917–957Google Scholar
  19. 19.
    Clark M: Antibody humanization: A case of the ‘Emperor's new clothes’? Immunol Today21: 397–402, 2000PubMedGoogle Scholar
  20. 20.
    Davis CG, Jia X-C, Feng X, Haak-Frendscho M: Production of Human antibodies from Transgenic Mice. 191–200, 2003Google Scholar
  21. 21.
    Hoogenboom HR, Henderikx P, de Haard H: Creating and engineering human antibodiesfor immunotherapy. Adv Drug Deliv Rev 31: 5–31, 1998PubMedGoogle Scholar
  22. 22.
    Noujaim AA, Schultes BC, Baum RP, Madiyalakan R: Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13–evidence for antibody-mediatedantigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm 16: 187–203, 2001CrossRefPubMedGoogle Scholar
  23. 23.
    Timmerman JM: Vaccine therapies for non-Hodgkin's lymphoma. Curr Treat Options Oncol3: 307–315, 2002PubMedGoogle Scholar
  24. 24.
    US Food and Drug Administration: Guidance for Industry: Continuous Marketing Applications: Pilot 1℄Reviewable Units for Fast Track Products Under PDUFA, 2003Google Scholar
  25. 25.
    US Food and Drug Administration: Guidance for Industry: Continuous Marketing Applications: Pilot 2℄Scientific Feedback and Interactions During Development of Fast Track Products Under PDUFA, 2003Google Scholar
  26. 26.
    US Food and Drug Administration: Guidance for Industry: Fast Track Drug Development Programs℄Designation, Development, and Application Review, 2004Google Scholar
  27. 27.
    Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in Ig G Fc receptor Fcgamma RIIIa gene. Blood 99: 754–758, 2002CrossRefPubMedGoogle Scholar
  28. 28.
    Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA: Polymorphisms in Fcgamma RIIIA (CD16) receptor expression are associated with clinical response torituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 23: 474–481, 2005CrossRefPubMedGoogle Scholar
  29. 29.
    Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independentlypredict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21: 3940–3947, 2003CrossRefPubMedGoogle Scholar
  30. 30.
    Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T, Ichinohasama R:Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma:application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int 51: 579–584, 2001CrossRefPubMedGoogle Scholar
  31. 31.
    McKeage K, Perry CM: Trastuzumab: A review of its use in the treatment of metastaticbreast cancer overexpressing HER2. Drugs 62: 209–243, 2002PubMedGoogle Scholar
  32. 32.
    Toi M, Takada M, Bando H, Toyama K, Yamashiro H, Horiguchi S, Saji S: Currentstatus of antibody therapy for breast cancer. Breast Cancer 11: 10–14, 2004PubMedCrossRefGoogle Scholar
  33. 33.
    Sugano M, Egilmez NK, Yokota SJ, Chen FA, Harding J, Huang SK, Bankert RB:Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastaticspread of established human lung tumor xenografts in severe combined immunodeficientmice. Cancer Res 60: 6942–6949, 2000PubMedGoogle Scholar
  34. 34.
    McNeil SE: Nanotechnology for the Biologist. J Leukocyte Biol 78: 585–594, 2005PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Wendy C. Weinberg
    • 1
  • Michelle R. Frazier-Jessen
    • 1
  • Wen Jin Wu
    • 1
  • Andrea Weir
    • 2
  • Melanie Hartsough
    • 2
  • Patricia Keegan
    • 2
  • Chana Fuchs
    • 1
  1. 1.Division of Monoclonal Antibodies, Office of Biotechnology Products, Office of Pharmaceutical ScienceCenter for Drug Evaluation and Research, Food and Drug AdministrationBethesda
  2. 2.Division of Biologic Oncology Products, Office of Oncology, Office of New DrugsCenter for Drug Evaluation and Research, Food and Drug AdministrationRockville

Personalised recommendations